Swiss pharmaceutical company Novartis (NYSE:NVS) has announced the acquisition of German biopharmaceutical company MorphoSys AG (NASDAQ:MOR) for €68 per share for a total of €2.7 billion ($2.9 billion) in cash. Shares of Morphosys ticked higher in pre-market trading and have surged more than 50% over the past five trading sessions.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Novartis has made this acquisition to expand its oncology pipeline and enhance its global presence in hematology. As a part of this acquisition, the company will own pelabresib (CPI-0610), which is used to treat myelofibrosis (a type of bone marrow cancer), and tulmimetostat (CPI-0209). Tulmimetostat (CPI-0209) is currently being tested in patients with solid tumors or lymphomas.
However, this transaction is subject to regulatory clearance and a minimum acceptance threshold of 65% from shareholders. The deal is expected to close in the first half of this year.
Is Morphosys a Buy or Sell?
Morphosys stock has soared by more than 200% over the past year. Overall, analysts remain bullish about MOR stock, with a Moderate Buy consensus rating based on three Buys and two Holds. The average MOR price target of $13.23 implies a downside potential of 17.8% from current levels if the acquisition falls through.
